Neurovascular Stent Market Size, Share & Trends Analysis | Global | 2026-2032 | Includes: Traditional Neurovascular Stents, Flow Diversion Stents, and 1 more

The global neurovascular stent market was valued at $660 million in 2025. The market is expected to grow at a compound annual growth rate (CAGR) of 3.7%, reaching $850 million by 2032.

This report covers traditional neurovascular stents, flow diversion stents, and intrasaccular stents. The report quantifies procedure numbers, unit sales, average selling prices (ASPs), market values, growth rates, and company shares, with historical data back to 2022 and forecasts through 2032.

The market is expected to demonstrate steady growth over the forecast period, driven by increasing adoption of minimally invasive treatments for complex aneurysms and vascular conditions. Flow diversion stents represent the largest portion of the market and continue to show solid growth supported by expanding clinical indications. Intrasaccular stents are growing at the fastest rate, reflecting rising physician preference for less invasive treatment options and broader adoption of newer technologies. Traditional neurovascular stents are the most mature segment, growing at a slower and more stable pace.

Technological advances in stent design, self-expanding materials, biocompatible coatings, and MRI-compatible construction are expanding the range of aneurysms that can be treated endovascularly. Improved imaging technologies are increasing the detection of unruptured aneurysms and expanding the treated patient population. Physician resistance among older-generation interventionalists and negative clinical trial results in specific intracranial stenosis indications are the primary structural constraints on market growth.

Market Overview

The global neurovascular stent market addresses the endovascular treatment of complex intracranial aneurysms, including wide-necked, fusiform, and dissecting presentations that are not amenable to simple coil occlusion. Three device categories serve distinct clinical roles within this space. Traditional neurovascular stents provide scaffolding to assist in the coiling of wide-necked aneurysms. Flow diversion stents redirect blood away from the aneurysm to promote thrombosis within the sac, primarily for large and giant aneurysms. Intrasaccular stents are deployed directly within the aneurysm to scaffold the neck and exclude the sac from circulation, offering a less invasive alternative to flow diversion for certain aneurysm morphologies.

Flow diversion stents represent the largest market segment, having established a strong clinical position as the preferred treatment for large and giant wide-necked aneurysms that are poorly suited to other endovascular approaches. The segment benefits from expanding approved indications and growing physician experience with flow diverter implantation. Intrasaccular devices are the fastest-growing segment, driven by increasing physician comfort with newer technology and the appeal of a device that can be delivered and positioned without the need to traverse the aneurysm neck with a conventional stent delivery system.

Technology advancement is the primary engine of market expansion. Self-expanding stent designs, improved biocompatible coatings, and MRI-compatible construction have made neurovascular stenting more practical, safer, and applicable to a wider range of anatomical presentations. As stents become smaller, they can be implanted in smaller arteries and more distal locations, expanding the treatable patient population. These advances are occurring more rapidly than can be fully characterized by clinical trial data, meaning real-world adoption frequently precedes the completion of formal evidence reviews.

Clinical evidence has played a mixed role in shaping this market. Negative results for intracranial stenting in the stenosis indication, established by the SAMMPRIS trial and confirmed by subsequent studies, led to FDA-imposed restrictions and a shift in practice away from stent-assisted coiling in certain settings. At the same time, the long-term evidence base for flow diversion in aneurysm treatment continues to build, and intrasaccular devices are accumulating data that supports broader adoption. The overall trajectory of clinical evidence is expected to support market expansion, though physician familiarity and interpretation of available data will continue to influence adoption speed across centers and geographies.

Market Drivers

Technological Advancement

Stent technology in the neurovascular space continues to improve across multiple dimensions, making procedures faster and easier while reducing patient risk and physician resistance. The introduction of self-expanding stent designs has been particularly significant, allowing stents to conform to vessel anatomy without the trauma associated with balloon-expandable deployment and enabling treatment of complex presentations including wide-necked, fusiform, and dissecting aneurysms. Improved biocompatible coatings and MRI-compatible materials have also addressed critical clinical concerns around thrombogenicity and post-implant imaging, expanding the practical usability of stents across patient populations. As stents become smaller and more deliverable, they can be implanted in smaller arteries and at more distal locations, broadening the anatomical scope of treatable cases. Continued innovation in neurovascular access devices is further supporting this expansion by enabling better stent delivery to difficult anatomy.

Improved Imaging Technologies

Advances in imaging technologies are increasing the detection rate of unruptured intracranial aneurysms, expanding the number of patients identified as candidates for endovascular treatment. Cerebral angiography, CT angiography, and MRI can all be used to detect unruptured aneurysms, and as imaging quality and availability continue to improve globally, more patients are being diagnosed before aneurysm rupture. An increase in the number of aneurysms detected translates directly into an increase in the number treated, which drives unit sales across all three neurovascular stent categories. Earlier detection also supports intervention before aneurysm enlargement or morphological changes complicate treatment, which can favor the use of stent-based approaches over more conservative management.

Market Limiters

Physician Resistance

Some physicians in the interventional neuroradiology community have displayed resistance to adopting neurovascular stents, partly because the technology is relatively new to the specialty and partly because it requires specialized training and procedural confidence that older-generation interventionalists may not have developed during their core training. Younger physicians and recent graduates who were trained with these devices from the outset are generally more comfortable with stenting and more likely to incorporate it into their practice. As more clinical data becomes available across indications and as stent technology continues to improve in terms of flexibility, positioning, and ease of deployment, physician resistance is expected to diminish progressively. However, during the current forecast period it remains a meaningful constraint on adoption speed in certain institutions and geographies where experienced endovascular practitioners trained before stent-based techniques were established.

Negative Clinical Results

Stent application for intracranial stenosis suffered a significant setback following the 2011 SAMMPRIS trial, which found that aggressive medical management was superior in efficacy to stenting for intracranial arterial stenosis. As a result of this trial, the FDA altered the criteria for intracranial stenting and a shift away from stent-assisted coiling in this indication began. The 2015 Vitesse Intracranial Stent Study for Ischemic Stroke Therapy confirmed the SAMMPRIS findings, reinforcing the practice change. A 2021 study indicated that stenting tended to be safer when performed closest to the qualifying event, providing some nuance to the overall picture. In the flow diversion segment, results from the Flow Diversion in Intracranial Aneurysm Treatment trials were published in June 2019 after the trial was cut short due to safety concerns, with 42% of patients allocated to flow diversion failing to reach the primary outcome compared to 36% in the standard treatment group. Further randomized trials are needed to clarify the role of flow diversion across aneurysm subtypes and patient populations, and uncertainty in the evidence base continues to moderate adoption in some clinical settings.

Market Coverage and Data Scope

• Quantitative coverage: Procedure numbers, market size, market shares, market forecasts, growth rates, units sold, and average selling prices.
• Qualitative coverage: Growth trends, market limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles and product portfolios, and technology trends shaping demand.
• Time frame: Base year 2025, forecasts 2026 to 2032, historical data 2022 to 2024.
• Data sources: Primary interviews with neurovascular device industry leaders and interventional neuroradiologists, regulatory data, hospital procurement data, import and export data, and the iData Research internal database.
• Care settings: Hospitals and neurovascular intervention centers.

Markets Covered and Segmentation

• The neurovascular stent market is analyzed across three device type categories, each assessed by procedure volume, unit volume, ASP, and market value with historical and forecast data:
• Traditional Neurovascular Stents
• Flow Diversion Stents
• Intrasaccular Stents

Competitive Analysis

Terumo held the leading position in the neurovascular stent market in 2025. The company offers the LVIS and LVIS Jr (Low-Profile Visualized Intraluminal Support) devices, which are designed to provide scaffold support for the coiling of wide-necked intracranial aneurysms. The low-profile design of the LVIS family allows delivery through smaller microcatheters and enables visualization of the stent during and after deployment, supporting precise placement in complex anatomy. Terumo's leadership in the stent segment is complemented by its broader commercial presence across the neurovascular device space.

Medtronic held the second-leading position in the global neurovascular stent market in 2025. The company competes through the Pipeline Flex, its current-generation flow diverting stent, as well as earlier Pipeline platform products. The Pipeline device redirects blood flow away from the aneurysm to promote thrombosis within the sac and is used primarily for large and giant wide-necked aneurysms. Medtronic's position in the flow diversion segment, which represents the largest share of market value within the neurovascular stent market, is a key driver of its overall competitive standing in this space.

Stryker was the third-leading competitor in the neurovascular stent market in 2025. The company competes through the Neuroform EZ stent system, a self-expanding open-cell stent designed for use as a scaffold to assist in the coiling of wide-necked intracranial aneurysms. The Neuroform EZ's delivery and positioning characteristics provide physicians with a tool for aneurysm stabilization during coil embolization in cases where the aneurysm neck geometry prevents reliable coil retention without stent support. Stryker's established neurovascular commercial presence supports its distribution of the Neuroform platform across major global markets.

Technology and Practice Trends

• Self-expanding stent adoption: Self-expanding designs are now standard across neurovascular stent platforms, allowing conformity to vessel anatomy without balloon deployment trauma and enabling treatment of complex aneurysm morphologies including fusiform and dissecting presentations.
• Flow diversion expansion: Flow diversion stents continue to expand their clinical indications beyond initial large aneurysm approvals, with growing physician experience and accumulating outcome data supporting broader adoption across aneurysm types.
• Intrasaccular device growth: Intrasaccular stents are the fastest-growing segment, offering physicians a less invasive deployment pathway and gaining adoption in aneurysm morphologies and patient profiles where traditional stent-assisted coiling or flow diversion carries greater procedural complexity.
• MRI-compatible and biocompatible materials: Improvements in stent material science are reducing thrombogenicity, improving post-implant imaging compatibility, and expanding the range of patients for whom stent-based treatment is practical and safe.
• Miniaturization for distal access: Ongoing reductions in stent delivery profile and diameter are enabling placement in smaller arteries and more distal locations, broadening the anatomical scope of treatable aneurysms.
• Imaging-driven diagnosis growth: Improvements in CT angiography and MRI are increasing the detection rate of unruptured aneurysms, expanding the eligible patient population and supporting procedure volume growth across all three stent categories.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

• Where are the largest and fastest-growing opportunities across traditional neurovascular stents, flow diversion stents, and intrasaccular stents through 2032?
• How are self-expanding designs, biocompatible coatings, and MRI-compatible materials expanding the range of aneurysms that can be treated endovascularly with stent-based approaches?
• What is the growth outlook for flow diversion stents as the largest market segment, and how are expanding clinical indications and accumulating outcome data shaping physician adoption?
• Why are intrasaccular devices the fastest-growing segment, and which aneurysm morphologies and patient profiles are driving this adoption?
• What is the lasting commercial and clinical impact of the SAMMPRIS trial and flow diversion safety concerns on stent use across indications and patient populations?
• Which companies lead each stent category and how are the LVIS, Pipeline Flex, and Neuroform EZ platforms differentiated by design, indication, and market positioning?
• How is improved imaging technology expanding the diagnosed aneurysm population and translating into incremental unit demand across all three stent device types?
• What are the key risks to market growth, including physician resistance, clinical evidence uncertainty, reimbursement variability, and competitive pressure from non-stent endovascular alternatives?

The Global Neurovascular Stent Market Report from iData Research answers these questions with procedure-aware models, company share analysis, and pricing detail across all three device categories. Use it to quantify demand, benchmark competitors, and plan commercial strategy across a steadily growing market shaped by technology advancement, evolving clinical evidence, and a shifting mix toward newer and faster-growing stent modalities.